Rick E. Winningham - 01 Mar 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TBPH
Reported as of: 01 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2023, 19:41:13 UTC
Prior SEC filing: 22 Feb 2023
Next SEC filing: 23 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Brett A Grimaud, Attorney-in-Fact

Key filing fact

Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 03 Mar 2023.

Key facts

This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2023, 19:41.

Change

Previous filing in this sequence was filed on 22 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +330,000
Change %: +25%
Price: $0.000000
Shares after: 1,643,377
Date: 01 Mar 2023
Ownership: Direct
Footnotes: F1

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,567
Date: 01 Mar 2023
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On March 1, 2023, the reporting person was granted 330,000 RSUs. 165,000 RSUs are subject to service-based vesting conditions and the remaining 165,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment.